Aims The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programme consisted of three parallel, randomised, double-blind clinical trials comparing candesartan with placebo in patients with heart failure (HF) categorised according to left ventricular ejection fraction and tolerability to an ACE inhibitor. We conducted a pharmacogenomic study of the CHARM studies to identify genetic predictors of heart failure progression and the efficacy and safety of treatment with candesartan.

中文翻译：

---

来自 CHARM 计划的心力衰竭和坎地沙坦反应的药物基因组学研究

目的坎地沙坦降低死亡率和发病率 (CHARM) 计划由三项平行、随机、双盲临床试验组成，在根据左心室射血分数和耐受性分类的心力衰竭 (HF) 患者中比较坎地沙坦与安慰剂ACE抑制剂。我们对 CHARM 研究进行了药物基因组学研究，以确定心力衰竭进展的遗传预测因子以及坎地沙坦治疗的有效性和安全性。